Bristol Myers Squibb Forecasts 2024 Adjusted EPS Of $0.75-$0.95 Versus Prior Guidance Of $0.60-$0.90 And Consensus Of $0.71
Bristol-Myers Squibb Company -1.04%
Bristol-Myers Squibb Company BMY | 54.14 | -1.04% |
Financial Guidance
Bristol Myers Squibb is raising its 2024 line-item guidance as noted below.
2024 Line-Item Guidance | ||
Non-GAAP2 | ||
July (Prior) |
October (Updated) |
|
Total Revenues | Upper end of low single- digit range |
~5% increase |
Total Revenues (excl. F/X) |
Upper end of low single- digit range |
~6% increase |
Gross Margin % | Between ~74% and ~75% | Between ~74.5% and ~75% |
Operating Expenses1 | Low single-digit increase | ~4% to ~5% increase |
Other income/(expense) | ~($50M) | ~$125M |
Effective tax rate | ~66% | ~60% |
Diluted EPS | $0.60 - $0.90 | $0.75 - $0.95 |